DeByle confirmed, "Q4 FY '25 showed operating expenses of $25 million versus $10.8 million in Q4 of FY '24," with GAAP ...
BACKGROUND: Despite antiplatelet therapy, some patients remain at high ischemic risk because of drug nonresponsiveness or high residual platelet reactivity). We aimed to target an orphan platelet GPCR ...
HIV-1 envelope glycoprotein (Env), a gp120–gp41 trimer, undergoes coordinated conformational changes that drive membrane fusion and allow immune evasion by transiently concealing ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する